Osteoarthritis (Xcel-m-condro-alpha)

Osteoarthritis (Xcel-m-condro-alpha)

Photo BST: Cleanroom at Xcelia

ITRT authorized to apply stem cell treatment because previous clinical trials.

This trial was sponsored by XCELIA (Advanced Therapies Division of the Banc de Sang i Teixits (BST)) and came under the macro research project MEDCEL. It included 15 patients with grades II and III osteoarthritis with no previous surgery. Patients were given an intra-articular injection of xcel-condro-alpha, which consists of autologous bone marrow mesenchymal progenitor cells selected and cultured with XCELIA GMP procedures.

Excellent results were obtained both in terms of improvement of the inflammatory and pain symptoms and rates of regeneration of the affected cartilage. The results are in the process of being published in influential scientific journals.

The AEMPS regularly authorises the research team to continue to use the therapy in the treatment of osteoarthritis of the knee with stem cells under their supervision, and restricted to suitably selected patients.

Link to Registry ClinicalTrial.gov

Última actualización: 26/11/2019